Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Formation of Lipopolysaccharides01:19

Formation of Lipopolysaccharides

Lipopolysaccharides (LPS) are crucial components of the outer membrane of Gram-negative bacteria, serving both structural and functional roles. It contributes to membrane stability and protects bacteria from host immune responses. LPS is composed of three major regions—lipid A, a core oligosaccharide, and an O antigen. The biosynthesis and assembly of LPS involve a highly coordinated set of enzymatic reactions and transport mechanisms. Additionally, LPS is recognized as an endotoxin, triggering...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Specialty pharmacy services compared with community-based pharmacy services on HIV viral load.

Journal of the American Pharmacists Association : JAPhA·2024
Same author

The efficacy of an alcohol-based nasal antiseptic versus mupirocin or iodophor for preventing surgical site infections: A meta-analysis.

American journal of infection control·2024
Same author

Home Monitoring for Fever: An Inexpensive Screening Method to Prevent Household Spread of COVID-19.

Journal of biotechnology and biomedicine·2024
Same author

Reflections on COVID-19: Solitude and Isolation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Lister Revisited - Skin Antisepsis before Fracture Fixation.

The New England journal of medicine·2024
Same author

Audio Interview: Preparing for the Next Pandemic.

The New England journal of medicine·2023

Related Experiment Video

Updated: Jul 18, 2026

Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids
11:56

Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids

Published on: May 4, 2018

Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent.

Patricia Fulco1, Richard P Wenzel

  • 1Virginia Commonwealth University, Department of Internal Medicine, Richmond, VA, USA. pfulco@mcvh-vcu.edu

Expert Review of Anti-Infective Therapy
|December 22, 2006
PubMed
Summary

Ramoplanin is a novel antibiotic effective against gram-positive bacteria, including vancomycin-resistant enterococci. Clinical trials show promise for preventing infections and treating Clostridium difficile.

More Related Videos

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

Related Experiment Videos

Last Updated: Jul 18, 2026

Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids
11:56

Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids

Published on: May 4, 2018

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Ramoplanin is a novel antibiotic targeting gram-positive bacteria by inhibiting peptidoglycan synthesis.
  • It acts by binding to lipid II, a crucial intermediate in bacterial cell wall formation.
  • Ramoplanin has received US FDA fast-track designation for enterococcal infections and Clostridium difficile treatment.

Purpose of the Study:

  • To evaluate the efficacy of ramoplanin in preventing enterococcal infections in carriers.
  • To assess ramoplanin's effectiveness in treating Clostridium difficile colitis.
  • To determine the clinical utility of ramoplanin in suppressing target organism carriage.

Main Methods:

  • Phase II trials were conducted, including a double-blind, placebo-controlled study in vancomycin-resistant enterococci carriers.
  • Equivalence of ramoplanin and vancomycin was assessed for C. difficile colitis treatment.
  • Minimum inhibitory concentrations (MIC90s) were determined against various gram-positive organisms.

Main Results:

  • Ramoplanin demonstrated potent activity with MIC90s <= 1.0 microg/ml against tested gram-positive bacteria.
  • A Phase II trial showed proof of concept for ramoplanin in suppressing target organism carriage.
  • Ramoplanin proved equivalent to vancomycin in treating C. difficile colitis.

Conclusions:

  • Ramoplanin exhibits significant potential as a therapeutic agent against challenging gram-positive pathogens.
  • Further Phase III trials are necessary to establish its definitive clinical value and role in therapy.
  • The antibiotic's ability to suppress organism carriage in the GI tract and nares requires further investigation.